Tag archive for ‘FDA AdCom action on Lipocine’s Tlando’
Antares Pharma: Update on Xyosted (ATRS, Buy, $2.34)
Regulatory Update Antares announced that it has scheduled a Type A meeting with FDA for Xyosted which is intended to resolve issues that have stalled the FDA regulatory review. Antares requested the meeting on December 21, 2017 in response to a Complete Response Letter on Xyosted. The meeting will take place on February 21, 2018. […]